CRISPR’s data hint allogeneic CAR Ts may have the efficacy and safety issues of autologous therapies 

CRISPR Therapeutics’ first allogeneic CAR T therapy readout supports the idea that the therapeutic class can yield efficacy on par with autologous CAR Ts, without causing graft-versus-host disease.

But a patient death raises the possibility allogeneic CAR Ts won’t escape the safety issues of their autologous counterparts.   ...